{
    "clinical_study": {
        "@rank": "77293", 
        "arm_group": [
            {
                "arm_group_label": "Prasugrel (60mg) 30 min post cangrelor", 
                "arm_group_type": "Experimental", 
                "description": "Administration of 60mg prasugrel 30 min post cangrelor infusion discontinuation"
            }, 
            {
                "arm_group_label": "Clopidogrel (600mg) within 5 min post cangrelor", 
                "arm_group_type": "Experimental", 
                "description": "Clopidogrel 600mg administered within 5 minutes after the discontinuation of the cangrelor infusion"
            }, 
            {
                "arm_group_label": "Clopidogrel (600mg) 0.5 hrs after cangrelor initiation", 
                "arm_group_type": "Experimental", 
                "description": "Clopidogrel 600 mg administered 0.5 hours following the initiation of cangrelor infusion"
            }, 
            {
                "arm_group_label": "Clopidogrel (600mg) 1.0 hr after cangrelor initiation", 
                "arm_group_type": "Experimental", 
                "description": "Clopidogrel 600 mg administered 1.0 hour following the initiation of cangrelor infusion"
            }, 
            {
                "arm_group_label": "Clopidogrel (600mg) 1.5 hrs after cangrelor initiation", 
                "arm_group_type": "Experimental", 
                "description": "Clopidogrel 600 mg administered 1.5 hours following the initiation of cangrelor infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "There are two separate objectives in this study:\n\n        1. to demonstrate the pharmacodynamic profile when patients treated with cangrelor are\n           switched to oral prasugrel administered 30 min after cangrelor infusion is discontinued\n           and\n\n        2. to demonstrate the pharmacodynamic profile when patients treated with cangrelor are\n           switched to clopidogrel 600mg administered during or immediately after the infusion."
        }, 
        "brief_title": "Cangrelor to Clopidogrel or Prasugrel Transition Study", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Greater than / equal to 18 and less than 75 years of age, of either sex, and of any\n             race.\n\n          2. Stable coronary artery disease defined by the following criteria:\n\n               1. Previous myocardial infarction defined by admission to the hospital with\n                  elevation of markers of injury or the presence of pathologic Q-waves on at least\n                  2 contiguous electrocardiogram (ECG) leads.\n\n                  OR\n\n               2. Previous revascularization by PCI or CABG, and\n\n               3. Treatment with ASA 81 mg daily.\n\n        Exclusion Criteria:\n\n          1. Known intolerance or contraindication to cangrelor or prasugrel, or any ingredients\n             of the respective formulation.\n\n          2. Any antiplatelet (other than aspirin) or anticoagulant medication with the previous\n             30 days.\n\n          3. Acute coronary syndrome within the previous 12 months.\n\n          4. History of bleeding diathesis or known coagulopathy such as; impaired hemostasis:\n             known international normalized ratio (INR) >1.5; past or present bleeding disorder\n             (including congenital bleeding disorders such as von Willebrand's disease or\n             hemophilia), acquired bleeding disorders, and unexplained clinically significant\n             bleeding disorders; thrombocytopenia (platelet count less than 100,000/\u00b5L), or\n             history of thrombocytopenia or neutropenia associated with clopidogrel.\n\n          5. Anemia (ie, hematocrit less than 35%).\n\n          6. Prior stroke (any type), prior cerebral anteriovenous malformation or intracranial\n             aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery).\n\n          7. Known or suspected pregnancy, or lactating females.\n\n          8. Known severe renal insufficiency (glomerular filtration rate [GFR] less than 30\n             mL/min).\n\n          9. Inability to provide informed consent.\n\n         10. Moderate or severe hepatic impairment as per investigator discretion (elevation of\n             liver function tests [LFTs]).\n\n         11. Inability to swallow oral medication at time of randomization.\n\n         12. Any clinically significant disease or condition affecting a major organ system,\n             including but not limited to gastrointestinal, renal, hepatic, endocrinologic,\n             broncho-pulmonary, neurological, or metabolic disease.\n\n         13. Any surgical or medical condition which, in the judgment of the Investigator, might\n             interfere with the pharmacokinetics, distribution, metabolism, or excretion of the\n             study drug (if applicable).\n\n         14. Treatment with other investigational medicinal products or devices within 30 days or\n             5 half-lives, whichever is longer, prior to the administration of the drug, or\n             planned use of investigational medicinal products or devices.\n\n         15. Subjects who, for any reason, are deemed by the Investigator to be inappropriate for\n             this study, including subjects who are unable to communicate or to cooperate with the\n             Investigator.\n\n         16. Subject is the Investigator or his/her deputy, research assistant, pharmacist, study\n             coordinator, other staff or relative thereof directly involved in the conduct of the\n             study.\n\n         17. Active pathological bleeding, or a history of transient ischemic attack."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979445", 
            "org_study_id": "MDCO-CAN-13-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Prasugrel (60mg) 30 min post cangrelor", 
                    "Clopidogrel (600mg) within 5 min post cangrelor", 
                    "Clopidogrel (600mg) 0.5 hrs after cangrelor initiation", 
                    "Clopidogrel (600mg) 1.0 hr after cangrelor initiation", 
                    "Clopidogrel (600mg) 1.5 hrs after cangrelor initiation"
                ], 
                "description": "Cangrelor administered as a 30 \u00b5g/kg bolus, followed by 4 \u00b5g/kg/min infusion for two hours", 
                "intervention_name": "Cangrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Clopidogrel (600mg) within 5 min post cangrelor", 
                    "Clopidogrel (600mg) 0.5 hrs after cangrelor initiation", 
                    "Clopidogrel (600mg) 1.0 hr after cangrelor initiation", 
                    "Clopidogrel (600mg) 1.5 hrs after cangrelor initiation"
                ], 
                "description": "Clopidogrel 600 mg single dose", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prasugrel (60mg) 30 min post cangrelor", 
                "description": "Prasugrel 60mg single dose", 
                "intervention_name": "Prasugrel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Cangrelor", 
                "Prasugrel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "CAD", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Burlington", 
                    "country": "United States", 
                    "state": "Vermont", 
                    "zip": "05401"
                }, 
                "name": "Fletcher Allen Health Care"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.", 
        "other_outcome": [
            {
                "measure": "Extent to which inhibitory effect of the oral thienopyridine is preserved at least 50% as measured flow cytometry", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Bleeding in accordance with GUSTO scale", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Assessment of adverse events   Assessment of adverse events   Assessment of Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "overall_official": {
            "affiliation": "Fletcher Allen Health Care", 
            "last_name": "David J. Schneider, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessment of pharmacodynamic effects  of terminal aggregation at 300 seconds (5 minutes) in response to in response to 20 \u00b5M ADP during and after discontinuation of cangrelor", 
            "measure": "Extent to which inhibitory effect of the oral thienopyridine is preserved at least 50% as measured by LTA.", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979445"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Extent to which inhibitory effect of the oral thienopyridine is preserved at least 50% as measured by PRU, VerifyNow\u00ae P2Y12 assay", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "source": "The Medicines Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Medicines Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}